US OptionsDetailed Quotes
INCY240816C70000
- 0.25
- +0.05+25.00%
15min DelayClose Aug 2 15:59 ET
0.48High0.20Low
0.28Open0.20Pre Close5 Volume255 Open Interest70.00Strike Price149.00Turnover53.38%IV8.97%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.2252Delta0.0465Gamma80.59Leverage Ratio-0.0778Theta0.0048Rho18.15Eff Leverage0.0363Vega
Incyte Stock Discussion
Sign in to post a comment
Morning Movers
Gapping up
$Paramount Global-B(PARA.US$ 's stock increased by 3.85% following a report from the New York Times that billionaire Barry Diller is considering a takeover bid for the company after the studio he used to lead withdrew from a merger with Skydance Media.
$PayPal(PYPL.US$ shares rose by 1.39% after Susquehanna raised its rating from Neutral to Positive.
Gapping down
$Tesla(TSLA.US$ 's stock declined ...
Gapping up
$Paramount Global-B(PARA.US$ 's stock increased by 3.85% following a report from the New York Times that billionaire Barry Diller is considering a takeover bid for the company after the studio he used to lead withdrew from a merger with Skydance Media.
$PayPal(PYPL.US$ shares rose by 1.39% after Susquehanna raised its rating from Neutral to Positive.
Gapping down
$Tesla(TSLA.US$ 's stock declined ...
31
2
I am currently a full-time NSF, and I have been investing in about 6-7 months.
I managed to garner an average of 3% a month the past 4 months using several methods of trading.
I started trading about 6 months ago with a small sum to test the waters until I was fully ready to begin my journey in March.
Trading is relatively simple if you just try to minimize your risk as much as possible and just throw that gambler's mindset into the bin...
I managed to garner an average of 3% a month the past 4 months using several methods of trading.
I started trading about 6 months ago with a small sum to test the waters until I was fully ready to begin my journey in March.
Trading is relatively simple if you just try to minimize your risk as much as possible and just throw that gambler's mindset into the bin...
+4
212
75
This month was a really chaotic month for me as it was very volatile with huge ups and downs.
My three biggest winners this month were INCY, APPL, and NVDA. Although my P/L could be higher if I did not sell my NVDA early, I still managed to reap the 5% gain in NVDA.
I believe NVDA holds massive growth potential as many companies have started shifting to NVDA, and AI hype will not seem to die down so soon. I will be expecting around 30 billion in revenue next quarter, which led me to buy ...
My three biggest winners this month were INCY, APPL, and NVDA. Although my P/L could be higher if I did not sell my NVDA early, I still managed to reap the 5% gain in NVDA.
I believe NVDA holds massive growth potential as many companies have started shifting to NVDA, and AI hype will not seem to die down so soon. I will be expecting around 30 billion in revenue next quarter, which led me to buy ...
11
5
This month was a really chaotic month for me as it was very volatile with huge ups and downs.
My three biggest winners this month were INCY, APPL, and NVDA. Although my P/L could be higher if I did not sell my NVDA early, I still managed to reap the 5% gain in NVDA.
I believe NVDA holds massive growth potential as many companies have started shifting to NVDA, and AI hype will not seem to die down so soon. I will be expecting around 30 billion in revenue next quarter, which led ...
My three biggest winners this month were INCY, APPL, and NVDA. Although my P/L could be higher if I did not sell my NVDA early, I still managed to reap the 5% gain in NVDA.
I believe NVDA holds massive growth potential as many companies have started shifting to NVDA, and AI hype will not seem to die down so soon. I will be expecting around 30 billion in revenue next quarter, which led ...
8
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
8
Meme stock volatility hit the market Monday, sending indexes higher, but shortly before noon EST, the market boomeranged back down. Just after the closing bell, the $S&P 500 Index(.SPX.US$ had fallen flatly 0.02%, the $Dow Jones Industrial Average(.DJI.US$ also declined 0.17%, and the $Nasdaq Composite Index(.IXIC.US$ climbed 0.28%.
MACRO
This week, investors can expect macroeconomic data prints in the form of PPI on Tuesday, and CPI prints Wednesd...
MACRO
This week, investors can expect macroeconomic data prints in the form of PPI on Tuesday, and CPI prints Wednesd...
+1
28
4
Morning Movers
Gapping up
$GameStop(GME.US$ shares surged over 37% in the premarket after "Roaring Kitty" posted for the first time in roughly three years.
$Arm Holdings(ARM.US$ shares increased by 3.4% following a report that the chip company plans to launch its first artificial intelligence chips next year.
$NVIDIA(NVDA.US$ shares added about 1% after Jefferies hiked its price target on the chipmaker to $1,200 a share, im...
Gapping up
$GameStop(GME.US$ shares surged over 37% in the premarket after "Roaring Kitty" posted for the first time in roughly three years.
$Arm Holdings(ARM.US$ shares increased by 3.4% following a report that the chip company plans to launch its first artificial intelligence chips next year.
$NVIDIA(NVDA.US$ shares added about 1% after Jefferies hiked its price target on the chipmaker to $1,200 a share, im...
26
Keep an eye on these M&As: 👀
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US$
$Johnson & Johnson(JNJ.US$ to acquire $ShockWave Medical(SWAV.US$
$Vertex Pharmaceuticals(VRTX.US$ to acquire $Alpine Immune(ALPN.US$
$Century Therapeutics(IPSC.US$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US$ to acquire Tenet Med.
$Incyte(INCY.US$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US$
...
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US$
$Johnson & Johnson(JNJ.US$ to acquire $ShockWave Medical(SWAV.US$
$Vertex Pharmaceuticals(VRTX.US$ to acquire $Alpine Immune(ALPN.US$
$Century Therapeutics(IPSC.US$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US$ to acquire Tenet Med.
$Incyte(INCY.US$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US$
...
7
Significant insider selling at Incyte and lack of purchases over the last year may suggest insiders don't view shares as a bargain. The history of sales makes us cautious about the stock.
1
Despite a recent earnings dip, Incyte's high P/E ratio indicates investor anticipation of strong future growth. This is expected to continue bolstering the share price unless earnings significantly deteriorate.
No comment yet
Ivo Stoyanov : ..
raz1 : how do iset my chart to see gaps